Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2002, for Bioanalytical Systems, Inc. (Note: The request metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.). The Company provides productivity tools, software, and research services to pharmaceutical and biotechnology firms globally, operating in two principal segments: analytical services and analytical products.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2002 | Nine Months Ended June 30, 2002 |
|---|---|---|
| Total Revenue | $6,576,000 | $19,984,000 |
| Gross Profit | $2,492,000 | $8,195,000 |
| Operating Income | $308,000 | $1,540,000 |
| Net Income | $281,000 | $1,047,000 |
| Diluted EPS | $0.06 | $0.23 |
| Cash and Equivalents (End of Period) | $209,000 | |
| Net Cash from Operating Activities (9mo) | $223,000 | |
| Revolving Line of Credit Outstanding | $3,303,000 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 2.8% for the quarter and 7.1% for the nine-month period compared to the prior year, driven primarily by increased service revenue from the bioanalytical services group.
- Margin Compression: Gross profit margins declined. Cost of service revenue increased to 74.6% of service revenue (from 65.4% prior year) due to increased staffing costs. Cost of product revenue rose to 41.5% (from 32.7%) due to product mix changes.
- Operating Expenses: General and administrative expenses increased 26.5% for the quarter and 20.9% for the nine months, primarily due to the reorganization of management functions at the preclinical operation. Selling expenses decreased due to lower foreign jobber commissions.
- Cash Flow: Net cash provided by operating activities dropped significantly to $223,000 for the nine months ended June 30, 2002, compared to $2,789,000 in the prior year. This was driven by a decrease in customer advances ($842,000 reduction), increased inventory levels, and decreased accounts payable.
- Capital Expenditures: Investing cash outflows surged to $3,786,000 (from $884,000 prior year) due to construction at the preclinical site and facility purchases.
Guidance, Outlook, and Material Events
- Mergers and Acquisitions:
- PharmaKinetics Laboratories, Inc. (PKLB): Entered into a Merger Agreement on June 20, 2002. PKLB shareholders will receive BAS common stock or convertible notes. The transaction is expected to close in the first quarter of the next fiscal year.
- LC Resources, Inc. (LCR): Reached an agreement in principle to acquire LCR for $2.5 million (cash and promissory notes). Closing is anticipated near the end of the current fiscal year, subject to financing.
- Facility Expansion: The Company is expanding facilities in Evansville, Indiana (approx. $3.5 million commitment, expected completion Dec 2002) and West Lafayette, Indiana (approx. $4.0 million commitment, expected completion Summer 2003). A new construction loan of $2,340,000 was obtained in August 2002 for the Evansville expansion.
- Liquidity: Management believes cash from operations and existing credit arrangements (including a $3.5 million revolving line of credit) will be sufficient to fund working capital and capital expenditure requirements.
- Accounting Changes: The Company will adopt SFAS No. 142 (Goodwill) effective October 1, 2002, which is expected to increase net income by approximately $77,000 annually by eliminating goodwill amortization.
Investor Verification Checklist
- Verify the status and closing conditions of the pending mergers with PKLB and LC Resources, Inc.
- Monitor the utilization of the $3.5 million revolving line of credit, which was nearly fully drawn ($3.3 million) at period end.
- Assess the impact of increased staffing costs on future service revenue margins.
- Confirm the timeline and funding sources for the $7.5 million in committed facility expansions.
- Review the Company's ability to maintain required financial ratios under its debt covenants given the recent increase in leverage.